Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kaleb Sharer"'
Autor:
Courtney L, Finch, Ian, Crozier, Ji Hyun, Lee, Russ, Byrum, Timothy K, Cooper, Janie, Liang, Kaleb, Sharer, Jeffrey, Solomon, Philip J, Sayre, Gregory, Kocher, Christopher, Bartos, Nina M, Aiosa, Marcelo, Castro, Peter A, Larson, Ricky, Adams, Brett, Beitzel, Nicholas, Di Paola, Jeffrey R, Kugelman, Jonathan R, Kurtz, Tracey, Burdette, Martha C, Nason, Irwin M, Feuerstein, Gustavo, Palacios, Marisa C, St Claire, Matthew G, Lackemeyer, Reed F, Johnson, Katarina M, Braun, Mitchell D, Ramuta, Jiro, Wada, Connie S, Schmaljohn, Thomas C, Friedrich, David H, O'Connor, Jens H, Kuhn
Publikováno v:
bioRxiv
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an exponentially increasing number of coronavirus disease 19 (COVID-19) cases globally. Prioritization of medical countermeasures for evaluation in randomized clinical trials is
Autor:
Courtney L. Finch, Ian Crozier, Ji Hyun Lee, Russ Byrum, Timothy K. Cooper, Janie Liang, Kaleb Sharer, Jeffrey Solomon, Philip J. Sayre, Gregory Kocher, Christopher Bartos, Nina M. Aiosa, Marcelo Castro, Peter A. Larson, Ricky Adams, Brett Beitzel, Nicholas Di Paola, Jeffrey R. Kugelman, Jonathan R. Kurtz, Tracey Burdette, Martha C. Nason, Irwin M. Feuerstein, Gustavo Palacios, Marisa C. St. Claire, Matthew G. Lackemeyer, Reed F. Johnson, Katarina M. Braun, Mitchell D. Ramuta, Jiro Wada, Connie S. Schmaljohn, Thomas C. Friedrich, David H. O’Connor, Jens H. Kuhn
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an exponentially increasing number of coronavirus disease 19 (COVID-19) cases globally. Prioritization of medical countermeasures for evaluation in randomized clinical trials is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cc6780e1114fd7aadc27dcb6f472a64
https://doi.org/10.1101/2020.05.14.096727
https://doi.org/10.1101/2020.05.14.096727